Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
April 23, 2024 15:56 ET
|
Day One Biopharmaceuticals, Inc.
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Co
National Year-over-Year (YoY) HPA in March was 5.7% and is projected to remain around 6% in April and May 2024
April 23, 2024 15:42 ET
|
American Enterprise Institute
National constant-quality home prices in March 2024 were up 1.5% from a month ago and 5.7% from a year ago (not seasonally adjusted).
Active Pharmaceutical Ingredient Market Trends Signal Growth Towards USD 446.6 Billion by 2032 With CAGR AT 6.4%
April 23, 2024 12:43 ET
|
Dimension Market Research
New York, April 23, 2024 (GLOBE NEWSWIRE) -- Overview According to Dimension Market Research, The Global Active Pharmaceuticals Ingredient Market size was valued USD 249.0 billion in 2023 and it...
The Bitcoin-Effect: How the Post-Halving Bitcoin Effect Can Take BlockDAG Network to $10 in 2025
April 23, 2024 11:45 ET
|
BlockDAG Network
London, UK, April 23, 2024 (GLOBE NEWSWIRE) -- The last few weeks in crypto have been nothing short of interesting and intense; Bitcoin’s highly anticipated halving took place while BlockDAG...
KULR Delivers Immediate Power Cell Battery Deployment Order for AI-Enabled Drone Missions in Ukraine
April 23, 2024 08:30 ET
|
KULR Technology Group, Inc.
(NYSE American: KULR) announced it has delivered, a power cell battery deployment order for AI-enabled drone and advanced air mobility missions in Ukraine.
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian Ray
April 23, 2024 08:00 ET
|
Recludix Pharma, Inc.
Newly appointed head of R&D, Dr. Nirula, joins Recludix from Eli Lilly with over two decades of clinical development experience SAB member, Dr. Ray, has over two decades of experience in...
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
April 23, 2024 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $370 - $390 million ––...
Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting
April 22, 2024 16:31 ET
|
Excision BioTherapeutics
Oral presentation to discuss CRISPR-associated gene editing inactivating herpes virusTwo poster presentations highlight the potential of EBT-104 for the treatment of HSV-1 Keratitis, demonstrating...
6G Market to Grow at CAGR of 30% through 2033; Robust Ecosystem of Telecom Operators, Equipment Manufacturers, Tech Companies & Research Institutions to Propel Growth
April 22, 2024 16:00 ET
|
The Brainy Insights
Newark, April 22, 2024 (GLOBE NEWSWIRE) -- The Brainy Insights estimates that the USD 5 billion in 2023 global 6G market will reach USD 68.92 billion in 2033. Sixth-generation (6G) wireless...
Wireless Broadband in Public Safety Market Worth $126.9 billion by 2029, Growing At a CAGR of 25.9% Report by MarketsandMarkets™
April 22, 2024 10:00 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, April 22, 2024 (GLOBE NEWSWIRE) -- The global Wireless Broadband in Public Safety Market size is estimated at USD 40.2 billion in 2024 to USD 126.9 billion by 2029, at a Compound Annual...